Pacira BioSciences Marks Milestone with New J-Code for EXPAREL
Pacira BioSciences Introduces New J-Code for EXPAREL
Pacira BioSciences, Inc. (NASDAQ: PCRX), a pioneer in innovative non-opioid pain management solutions, has made significant strides in the healthcare field with the announcement of a new Healthcare Common Procedure Coding System (HCPCS) J-code for its product, EXPAREL (bupivacaine liposome injectable suspension). Effective from January 1, 2025, this J-code (J0666) is expected to revolutionize billing and reimbursement procedures, leading to more efficient access to this effective pain management therapeutic.
Understanding the Importance of J-Codes
J-codes serve as reimbursement identifiers utilized by Medicare, commercial insurers, and various government payers for specific drug therapies. By establishing J0666 for EXPAREL, medical providers can streamline claims submissions more effectively. This new coding is not only significant for reimbursement when used in outpatient settings but also for office-based surgical procedures. This enhancement represents a critical improvement in the overall reimbursement landscape for EXPAREL, making it easier for healthcare practitioners to provide patients with necessary pain relief options.
Company Perspective on the J-Code
Frank D. Lee, the Chief Executive Officer of Pacira, expressed satisfaction regarding the new product-specific J-code. In his words, "Having a distinct J-code for EXPAREL will facilitate a smoother reimbursement process and is anticipated to increase recognition and coverage by commercial payers. As more clinicians gain access to EXPAREL, they will be better equipped to provide top-tier non-opioid pain management solutions to their patients." This proactive measure reflects Pacira's commitment to improving patient outcomes through greater accessibility to their innovative products.
EXPAREL: Transformative Pain Management Therapy
EXPAREL has garnered recognition for its effectiveness as a long-acting local analgesic indicated for patients aged six years and older. The product is designed to offer postsurgical local analgesia via infiltration and provides regional analgesia for adults through specific nerve blocks like the interscalene brachial plexus and sciatic nerve blocks. This clinical adaptability is evidenced by its use in over 15 million patients throughout the nation, highlighting its significance in pain management.
Pacira’s Portfolio of Pain Management Solutions
Beyond EXPAREL, Pacira boasts a robust lineup of non-opioid therapies aimed at pain management. This includes ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an injection for osteoarthritis knee pain management, and ioveraº, a groundbreaking handheld device that employs cold temperature therapy for immediate, long-lasting pain relief. Pacira's innovative solutions underscore its position as a leader in the non-opioid pain management market, striving to provide alternatives that prioritize patient well-being and minimize the risks associated with opioid use.
Future Directions for Pacira BioSciences
Looking ahead, Pacira is focused on enhancing the capabilities of its current products and expanding access to non-opioid treatment options. The advent of the new J-code for EXPAREL will empower healthcare providers to efficiently incorporate this innovative pain management solution into patient care, allowing them to transition more procedures to outpatient settings. This evolution aligns with broader healthcare trends towards increasing outpatient care efficiency and improving patient safety.
Engaging with Healthcare Providers
By providing educational resources and materials, Pacira ensures that healthcare practitioners are well-informed about the benefits and applications of EXPAREL and its associated products. This commitment to education not only strengthens relationships with healthcare professionals but also fosters a deeper understanding of modern pain management approaches. As the healthcare landscape evolves, Pacira BioSciences is dedicated to leading the charge in delivering innovative solutions that enhance patient care.
Frequently Asked Questions
What is the new J-code for EXPAREL?
The new J-code established for EXPAREL is J0666, effective January 1, 2025.
Why is the J-code significant for EXPAREL?
This J-code facilitates standardized billing and reimbursement for EXPAREL, enhancing access for patients and healthcare providers.
How does the J-code impact reimbursement?
With the J-code, acquisition and outpatient treatment of EXPAREL will receive separate and streamlined reimbursements, benefiting clinicians and patients alike.
What other products does Pacira offer?
In addition to EXPAREL, Pacira offers ZILRETTA for osteoarthritis pain management and ioveraº, a device for cold temperature pain relief.
What are Pacira's future goals?
Pacira aims to expand access to non-opioid solutions and continue improving patient outcomes through innovative healthcare delivery models.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- EMCOR Group, Inc. Announces Quarterly Dividend for Shareholders
- Pinnacle Gastroenterology Streamlines Care with Innovative AI
- PlayStar Elevates Engagement with New Jersey Devils Partnership
- EVgo Inc. Secures Major Funding for Charging Infrastructure
- KPS Global Teams with ISN for Improved Safety Management
- XTM Inc. Welcomes New CFO Following Trading Resumption
- Exciting Transformations Await Life Sciences Events in 2025
- Unlocking Cyber Resilience: Join Our ASM Webinar with Criminal IP
- Cyberimpact Enhances Marketing with New Landing Pages Feature
- Empowering Businesses: Strengthening IT Security with Bit-Wizards
Recent Articles
- Carpenter Technology Corporation's Upcoming Earnings Call Insights
- Exploring the Next Big Breakout Restaurant Stocks
- Spectral AI Revolutionizes Wound Care with New Technology
- D-BOX Technologies Announces Departure of Board Member
- How to Enhance Retirement Income with Social Security Strategies
- Exploring Opportunities: CMC Metals' Groundbreaking Projects
- Marjorie Taylor Greene's Strategic Stock Acquisitions Revealed
- Constellation Brands Unveils Strong Second Quarter Results
- FirstService to Reveal Q3 Financial Outcomes Soon
- FTI Consulting's Upcoming Financial Results and Insights
- Employee Election Results for AKVA Group ASA Board Members
- U.S. Economy Demonstrates Strong Resilience Amid Global Challenges
- Nykredit Realkredit A/S Adjusts Coupon Rates on Bonds
- DexCom, Inc. Shareholder Alert: Important Class Action News
- Alphamin Reports Strong Q3 FY2024 Results with Dividend Boost
- Class Action Insights for Extreme Networks Shareholders
- Hellas Gold and Eldorado Gold Support Scholarship for Greek Students
- Arch Biopartners Secures Debt Settlement Through Unit Issuance
- Urgent Update for Investors in Super Micro Computer Stocks
- Costamare Inc. Elects New Class II Directors at Stockholder Meeting
- Acadia Healthcare Faces Securities Investigation and Losses
- Ford Motor Company Faces Legal Challenges: What You Need to Know
- Automotive Collision Repair Market Set for Robust Growth
- Altius Minerals Highlights Q3 2024 Project Generation Growth
- D-BOX Technologies Inc. Board Resignation and Future Steps
- Innovative Digital Solutions Tackling Healthcare Staffing Issues
- Elevai Biosciences Secures New Patents for Innovative Treatment
- IBAT Launches Innovative Loan Marketplace for Community Banks
- Worksport Ltd Expands Government Sales and Sustainable Offerings
- FirstService Corporation Sets Date for Q3 Financial Results
- Howard Hughes Begins New Luxury Project at The Woodlands
- Curaleaf Opens New Dispensary in Florida, Expanding Access
- ZK International Achieves Key Contract to Boost Gas Infrastructure
- Vistra Energy Achieves Higher Stock Target Amid Market Changes
- i3 Verticals' Strategic Shift Boosts Confidence in Future Growth
- New Horizons for 1101 White Cliff with $21 Million Property Deal
- Targa Resources Sees Promising Future with New Projects in 2024
- Elevai Labs Targets Obesity with Innovative EL-22 Patents
- Soligenix and Sterling Pharma Solutions Join Forces for Growth
- Impact of Desktop Metal's Merger Approval on 3D Printing
- September Sees Slight Decrease in Planned US Layoffs Amid Economic Shifts
- Amazon Aims to Recruit 250,000 Workers This Holiday Season
- Truist Adjusts Tesla Price Target Amid Market Changes
- Air France-KLM Implements Strategic Cost-Cutting Measures
- Top Stocks to Consider as S&P 500 Faces Market Resistance
- Market Watch: Economic Focus Amid Mideast Turmoil
- Murphy Oil Corporation Unveils Early Tender Results for Debt
- Snap-on Incorporated Plans to Broadcast Third Quarter Results
- Gold Reserve's Update Signals Progress in Sale Proceedings
- Orbis Medicines Unveils R&D Expansion at Copenhagen Hub